Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Download Data

Freeline Therapeutics Holdings Plc Sales to Fixed Assets Ratio 1 year YoY Change (%) for the quarter ending September 20, 2024

Freeline Therapeutics Holdings Plc Sales to Fixed Assets Ratio 1 year YoY Change (%) is NA for the quarter ending September 20, 2024. Sales to fixed assets ratio measures the revenue generated by a company relative to its fixed assets, such as property, plant, and equipment. It is calculated by dividing the revenue by the net value of fixed assets. This ratio provides insights into the efficiency of the company's fixed assets in generating sales revenue. A higher sales to fixed assets ratio suggests better sales generation from fixed assets and efficient utilization of physical infrastructure. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Freeline Therapeutics Holdings Plc Sales to Fixed Assets Ratio for the quarter ending September 30, 2022 was 0.00, a 0.00% change year over year.
  • Freeline Therapeutics Holdings Plc Sales to Fixed Assets Ratio for the quarter ending September 30, 2021 was 0.00.
NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO Mr. Michael J. Parini J.D.
IPO Date Aug. 7, 2020
Location United Kingdom
Headquarters Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees 152
Sector Healthcare
Industry Biotechnology
Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Similar companies

AVRO

AVROBIO Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email